Arbor Biotechnologies nets $215M

By The Science Advisory Board staff writers

November 9, 2021 -- Biotechnology company Arbor Biotechnologies recently raised $215 million in a series B financing round to move its lead programs for liver and central nervous system diseases to the clinic.

Arbor will continue to invest in its novel discovery engine to develop the next generation of gene editing technology, the company said in a release.

The round was led by Temasek, Ally Bridge Group, and TCG Crossover. Chen Yu, a managing partner at TCG Crossover, will join Arbor's board of directors.

To date, Arbor has raised over $300 million.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.